Ocular Manifestations of Systemic Lupus Erythematosus and Systemic Lupus Erythematosus with Antiphospholipid Syndrome. by Vijaybabu Sathishkumar, J R S
OCULAR MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS 
AND SYSTEMIC LUPUS ERYTHEMATOSUS WITH   
ANTIPHOSPHOLIPID SYNDROME 
 
 
 
 
                                                            DISSERTATION 
Submitted in partial fulfilment of the requirement for the degree of 
                         D.M. BRANCH IX – RHEUMATOLOGY 
 
 
                                                                                                             
 
 
             THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY 
                                       CHENNAI – 600032 
                                          AUGUST ‐ 2010 
 
 
                                                    CERTIFICATE 
 
                                                         This is to certify that the Dissertation entitled,  
“Ocular manifestations of Systemic Lupus Erythematosus and Systemic 
Lupus Erythematosus with Antiphospholipid Syndrome” is the bonafide 
record work done by Dr.J.R.S.VIJAYBABU SATHISHKUMAR, under our 
guidance and supervision in the Department of Rheumatology, Government General 
Hospital, Madras Medical College, Chennai, submitted as partial fulfilment for the 
requirements of D.M. Degree examination Branch IX, RHEUMATOLOGY AUGUST 
2010, under The Dr.M.G.R. Medical University, Chennai. 
 
 
 
Dr.J.MOHANA SUNDARAM M.D.,Ph.D.,            Dr.R.PORKODI M.D.,D.M., 
THE DEAN,                                                                PROFESSOR AND HEAD, 
MADRAS MEDICAL COLLEGE,                               DEPARTMENT OF RHEUMATOLOGY,                             
CHENNAI.                                                                  MADRAS MEDICAL COLLEGE,                                                        
                                                                                    CHENNAI.   
 
 
 
 
 
 
 
                                         ACKNOWLEDGEMENT 
                       I sincerely thank the Dean, Dr.J.MOHANASUNDARAM 
M.D.,Ph.D.,D.N.B., for having permitted me to carry out this dissertation work at 
Government General Hospital, Madras Medical College, Chennai. 
                            I have great pleasure in expressing my gratitude and respect for 
Dr.R.Porkodi M.D.,D.M., Additional Professor and Head, Department of 
Rheumatology, Madras Medical College, Chennai, for her valuable suggestions, kind 
guidance, constant supervision and moral support without which this study would 
not have been possible. 
                            I am thankful to Dr.J.Sasikala Stephen M.D., Additional 
Professor, Department of Rheumatology, Madras Medical College, Chennai, for her 
valuable guidance. 
                             My sincere thanks to our Readers, Dr.S.Rukmangatharajan 
M.D., D.M., and Dr.S.Rajeshwari M.D., D.M., and our Assistant Professors 
Dr.R.Ravichandran M.D., D.M., Dr.T.N.Tamilselvam M.D.,D.M., and 
Dr.S.Balameena  M.D., D.M., Department of Rheumatology, Madras Medical 
College, Chennai, for their valuable guidance, advice and suggestions for doing this 
study meticulously. 
                              I am extremely thankful to Dr.M.Radhakrishnan M.S.,D.O., 
Director, Regional Institute of Ophthalmology and Government Ophthalmic 
Hospital, Chennai, for permitting to carry out ophthalmic evaluation for  this work at 
the Regional Institute of Ophthalmology, Chennai. I am thankful to all Assistant 
Professors of Regional Institute of Ophthalmology, for helping me by doing 
ophthalmic evaluation without whose help the study would not have been possible. 
                                            I am very much thankful to the laboratory personnel 
Mrs.Kumudha Manoharan, Mrs.C.Radhabai Mrs.V.Sumathi, 
Mr.V.Balasubramanyam, Mr.M.Balasubramani ,  and Mrs.R.Eswari for 
their invaluable help in carrying out the Immunological investigations without which 
this work would not have been possible. 
                                            I am particularly thankful to Dr.Kathiravan 
M.V.Sc.,Ph.D., Associate Professor, Government Vetenary College, Chennai, for 
statistical analysis and all the paramedical staff members in the Department of 
Rheumatology, Madras Medical College, Chennai for their full co-operation in 
conducting the study. 
                                              Last but not the least, my sincere thanks to the patients who 
co-operated for this study, without whom the study could not have been completed 
and all my colleagues who shared their knowledge. 
 
 
 
 
 
 
 
 
 
 
 
                                            CONTENTS 
S.NO                        TOPICS                                                        PAGE NUMBER 
1    INTRODUCTION                                                              01   
         
2    REVIEW OF LITERATURE                                               04   
 
3    AIM                                                                                    29   
 
4    MATERIALS AND METHODS                                         30  
 
5    RESULTS                                                                            40 
 
6    DISCUSSION                                                                     51       
 
7    CONCLUSION                                                                   56  
 
    BIBLIOGRAPHY 
 
    APPENDICES 
 
 
 
 
  
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              OCULAR MANIFESTATIONS OF SYSTEMIC LUPUS  
      ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS       
                     WITH ANTIPHOSPHOLIPID SYNDROME  
INTRODUCTION 
                                  Systemic Lupus Erythematosus (SLE) is a chronic, relapsing and 
remitting, autoimmune disorder. The clinical presentations are diverse and depend 
on the organ systems involved. Potentially life-threatening complications may occur. 
A pathologic immune response involving the production of autoantibodies and 
immune complex mediated tissue damage is thought to play a central role in the 
disease process . Genetic, environmental, and possibly hormonal influences may also 
be contributing factors.  
                                Women with SLE outnumber men by 9 : 1 and the peak age of onset 
ranges from the late teens to the fourth decade of life. Individuals of African or Asian 
descent appear to be at greatest risk for developing the condition. Systemic treatment 
options generally include antimalarial drugs, corticosteroids, and other 
immunosuppressive agents. A variety of newer targeted treatment modalities are 
under development. 
                                    The ophthalmic manifestations of systemic lupus erythematosus (SLE) 
are protean. They range from lesions of the eyelid and secondary Sjogren’s syndrome to 
sight-threatening disorders such as retinal vascular disease and neuro-ophthalmic 
involvement. Retinal vascular disease can present as cotton wool spots, intraretinal 
haemorrhages or retinal vaso-occlusive disease with poor visual outcome. Severe retinal 
vaso-occlusive disease is reported to be significantly associated with central nervous system 
involvement. Visual loss from neuro-ophthalmic involvement is often due to lupus optic 
neuropathy. Other neuro-ophthalmic manifestations include cranial nerve palsies secondary 
to lupus microangiopathy and retrochiasmal disorders of vision. Choroidopathy is an 
uncommon cause of visual loss but cases have been documented in which there was serous 
elevation of the retinal pigment epithelium and sensory retina. Decreased perfusion of the 
choroid has also been demonstrated in some patients with SLE. 
                                         Drugs used in the treatment of SLE can also affect the eyes. The 
mainstay of treatment of SLE is oral corticosteroids. Well-known complications of 
corticosteroid therapy include posterior subcapsular cataract formation and glaucoma. 
                                     Dysfunction in immune regulation plays the principal role in the 
pathogenesis of SLE. Hyperreactivity of B-cells, producing a spectrum of 
autoantibodies, is primarily responsive for the immune dysregulation, although T-
cells are involved in the pathogenesis as well. The tissue injury is caused by immune 
complexes, deposition of which induces cell infiltration and damage to the tissue by 
proteolytic and collagenolytic enzymes.  
                                         Histopathology of affected tissue reveals vasculitis with 
fibrinoid necrosis and deposition of immunoglobulin and complement in small 
vessels and capillaries. Renal involvement begins with deposition of immune 
complexes in the glomeruli. Mesangial proliferation, glomerular necrosis, hyaline 
thrombus formation, and interstitial damage determine the severity of kidney 
disease.   
                                            In the eye, immune complex deposits in the vascular 
endothelium of the conjunctiva, sclera, choroid, ciliary body and retina alter the 
tissue structure and compromise function. Deposits can also develop in the basement 
membrane of the ciliary body, cornea and along the peripheral nerves of the ciliary 
body and conjunctiva.  
                                          While most patients with retinopathy have systemic disease, 
retinopathy can also occur independently of systemic flare-ups. SLE patients with 
retinopathy have a higher morbidity risk.  
                                        Unfortunately , ocular involvement is neglected in the 
classification criteria for SLE. Therefore a patient with arthritis, leukopenia, renal 
failure, and ocular involvement, as in the above reported patient, is not diagnosed 
with SLE. Consequently, appropriate treatment and monitoring is delayed and the 
generally poor prognosis of SLE becomes even worse in such cases.  
                                         This study was taken up to assess the frequency of eye changes 
among patients with SLE and SLE with antiphospholipid syndrome (APS). 
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                 REVIEW OF LITERATURE 
                                    Autoimmune disorders affect approximately 5% of the population 
in the Western world and there are about 80 different autoimmune diseases[1]. An 
autoimmune disease is a condition in which injury to the organs or tissues is caused 
by autoreactive antibodies or cells. Systemic lupus erythematosus (SLE) is 
considered a prototypic human autoimmune disease, which manifests itself with a 
variety of fascinating clinical and immunological features. 
                                    Systemic lupus erythematosus (SLE) is a multisystem disease 
that is caused by antibody production and complement-fixing immune complex 
deposition that result in tissue damage. 
 EPIDEMIOLOGY:   
                                    Prevalence rates in SLE are estimated to be 51 per 100,000 in the 
United States.[2] The incidence of SLE has nearly tripled in the last 40 years, mainly 
as a result of improved diagnosis of mild disease.[3] Women are affected nine times 
more frequently than men. The disease seems to be more common in urban than 
rural areas. Of patients with SLE, 65% have disease onset between ages 16 and 55, 
20% present before age 16, and 15% present after the age of 55.[4] Men with SLE tend 
to have less photosensitivity, more serositis, an older age at diagnosis, and a higher 1-
year mortality compared with women.[5]  SLE tends to be milder in the elderly with a 
lower incidence of malar rash, photosensitivity, purpura, alopecia, Raynaud's 
phenomenon, renal system involvement, and central nervous system (CNS) 
involvement, but a greater prevalence of serositis, pulmonary involvement, sicca 
symptoms, and musculoskeletal manifestations.[6] 
CLASSIFICATION CRITERIA: Criteria for SLE classification were developed in 
1971, revised in 1982, and revised again in 1997.[7] 
          The 1997 Revised Criteria for the Classification of Systemic Lupus Erythematosus (SLE)
Criterion Definition 
1. Malar rash Fixed malar erythema, flat or raised 
2. Discoid rash  Erythematous-raised patches with keratotic scaling and 
follicular plugging; atrophic scarring may occur in older
lesions 
3. Photosensitivity Skin rash as an unusual reaction to sunlight, by patient
history or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulcers, usually painless, observed
by physician 
5. Arthritis Nonerosive arthritis involving two or more peripheral 
joints, characterized by tenderness, swelling, or effusion 
6. Serositis a. Pleuritis (convincing history of pleuritic pain or rub
heard by physician or evidence of pleural effusion)
                                       OR 
b. Pericarditis (documented by ECG, rub, or evidence of 
pericardial effusion) 
7. Renal disorder A .Persistent proteinuria(>0.5g/d or >3+) 
                                       OR 
b. Cellular casts of any type 
8. Neurologic disorder a. Seizures (in the absence of other causes) 
                                       OR 
b. Psychosis (in the absence of other causes) 
9. Hematologic disorder a. Hemolytic anaemia  
                                            OR 
b. Leukopenia (<4,000/mL on two or more occasions) 
                                            OR 
c. Lymphopenia (<1,500/mL on two or more occasions) 
                                             OR 
d. Thrombocytopenia (<100,000/mL in the absence of 
offending drugs) 
10. Immunologic disorder a. Anti-double-stranded DNA 
                                              OR 
b. Anti-Sm 
                                              OR 
c. Positive finding of antiphospholipid antibodies based on 
(1) an abnormal serum level of IgG or IgM anticardiolipin 
antibodies, (2) a positive test result for lupus anticoagulant 
using a standard method, or (3) a false-positive serologic 
test for syphilis known to be positive for at least 6 months 
and confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test 
11. Antinuclear antibody An abnormal titer of antinuclear antibody (ANA) by
immunofluorescence or an equivalent assay at any time
and in the absence of drugs known to be associated with
drug-induced lupus syndrome. 
For identifying patients in clinical studies, a person shall be said to have SLE if any 
four or more of the 11 criteria are present, either serially or simultaneously, during any 
interval of observation. 
From Hochberg MG. Updating the American College of Rheumatology revised criteria 
for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 
1997;40:1725. 
 
ACTIVITY AND DAMAGE INDICES:  
                                      SLE has a chronic course that is often complicated by
exacerbations and flares of varying severity. Several validated global and organ-
specific activity indices are widely used in the evaluation of SLE patients.[8]  These 
include British Isles Lupus Assessment Group Scale, European Consensus Lupus
Activity Measure (ECLAM), Lupus Activity Index, National Institutes of Health SLE 
Index Score, Systemic Lupus Activity Measure, and Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI). The Systemic Lupus International Collaborating
Clinics/ACR damage index is a validated instrument specifically designed to ascertain 
damage in SLE.[9] The damage in SLE may be due to SLE itself or to drug therapy. The
index records damage in 12 organs or systems. There is no index to measure damage
caused by drugs in SLE at present. 
 
CLINICAL FEATURES: 
MUCOCUTANEOUS INVOLVEMENT:  
                                       Clearly, the cutaneous system is one of the most commonly 
affected, approaching 80% to 90%. The malar rash occurs in sun-exposed areas, such 
as nose and cheeks, and spares the nasolabial folds and below the nares. Discoid 
lupus lesions occur in these areas and also in the ears and scalp. Discoid lesions often 
heal with hypo- or hyperpigmentation. Subacute cutaneous lupus, which may be 
mistaken for a fungal rash, occurs as a psoriasiform type or an annular type. About 
half of patients with subcutaneous lupus have systemic lupus erythematosus. Livedo 
reticularis occurs with or without antiphospholipid antibodies. Nail fold capillary 
changes can be seen. A rare lupus rash, bullous lupus, presents as blistering lesions. 
Lupus panniculitis (also called "lupus profundus") can heal with a cavitating 
appearance because of fat necrosis. 
                                        Cutaneous lesions in SLE can be classified as lupus specific and 
nonspecific . The lupus-specific lesions can be subclassified further as acute, 
subacute, and chronic lesions.[10]  
 The Gilliam Classification of Lupus Erythematosus  (LE)-Associated Skin 
Lesions: 
I. Histopathologically Specific (LE-Specific) 
A. Acute cutaneous LE  
1. Localized  
2. Generalized  
B. Subacute cutaneous LE  
1. Annular  
2. Papulosquamous  
C. Chronic cutaneous LE  
1. Classical DLE  
a. Localized  
b. Generalized  
2. Hypertrophic (verrucous) DLE  
3. Lupus profundus (LE panniculitis)  
4. Mucosal LE  
5. LE tumidus  
6. Chilblains LE (perniotic LE)  
DLE, discoid lupus erythematosus; LE, lupus erythematosus. 
Musculoskeletal: 
                                      Polyarthralgias and polyarthritis eventually occur in 90% of SLE 
patients. The arthritis is usually nonerosive, involving the small joints of the hands 
(proximal interphalangeal and metacarpophalangeal joints, but not distal 
interphalangeal joints) and wrists initially. If deformities occur, they are usually 
reversible ("Jaccoud arthropathy"), because they are due to tendon and ligament 
laxity, not to bone erosions. Myositis, or an overlap with dermatomyositis, is rarely 
found. As many as 30% of SLE patients have coexisting fibromyalgia, which is a 
noninflammatory chronic pain syndrome, presenting with symmetric tender points 
above and below the waist. Radiologic features in lupus hand arthritis include 
scapholunate dissociation, joint space narrowing, cystic change, and palmar/ulnar 
subluxation in the wrist. Tenosynovitis, tendon rupture, flexor tendon contracture, 
septic arthritis, subcutaneous nodules and periarticular calcification have all been 
reported in SLE patients. 
                                     Generalized myalgia and muscle tenderness are common. 
Inflammatory myositis involving the proximal muscles has been reported to occur in 
5% to 11% of patients and may develop at any time during the course of the disease. 
The histologic features of myositis in SLE may be less striking than in idiopathic 
polymyositis. Histologic features include muscle atrophy, microtubular inclusions, 
and a mononuclear cell infiltrate. Fiber necrosis is an uncommon finding, but 
immunoglobulin deposition is almost always present despite the rarity of concurrent 
inflammation.[11]  
                                    Avascular necrosis of bone is a major cause of significant 
morbidity and disability in patients with SLE. Symptomatic avascular necrosis occurs 
in 5% to 12% of SLE patients. Higher prevalences have been reported in series that 
used MRI for its detection. In SLE, factors that can induce ischemia leading to bone 
necrosis include Raynaud's phenomenon, vasculitis, fat emboli, corticosteroids, and 
antiphospholipid antibody syndrome (APS). 
Renal:  
                                    The kidney is considered by many to be the signature organ 
affected by SLE. Renal involvement is a major cause of morbidity and hospital 
admissions in SLE patients and occurs in 40% to 70% of all patients. Generally, renal 
involvement tends to occur within the first 2 years of SLE with its frequency 
decreasing significantly after the first 5 years of disease.  Initial categories of lupus 
nephritis were based on classification by the World Health Organization as assessed 
by histology and location of immune complexes[12]. Recently, this classification has 
been revised by the International Society of Nephrology and Renal Pathology Society 
(ISN/RPS)[13] . 
             WORLD  HEALTH  ORGANIZATION  CLASSIFICATION  OF  LUPUS  NEPHRITIS               
                         
                                   The most severe form of lupus nephritis is diffuse proliferative 
glomerulonephritis. There are subendothelial immune complex deposits. This 
disorder can rapidly lead to renal failure. Usually, the urinalysis shows proteinuria, 
hematuria, and if a first morning urine is obtained, red blood cell casts . Focal lupus 
nephritis (class III) is less severe, but occasional patients do progress to renal failure. 
In membranous lupus nephritis there are subepithelial immune complex deposits 
with concomitant mesangial deposits. Patients usually have nephrotic syndrome. Its 
course is more indolent, but there is eventual progression to renal insufficiency and 
failure. Nephrotic syndrome is not to be considered benign, because it causes 
hyperlipidemia and hypercoagulability.  
 NERVOUS SYSTEM INVOLVEMENT:  
                                   SLE affects the CNS and the peripheral nervous system. 
Approximately 40% of the NPSLE manifestations develop before the onset of SLE or 
at the time of diagnosis, and 63% develop within the first year after the diagnosis.[15] 
              
                 Neuropsychiatric Syndromes in Systemic Lupus Erythematosus 
Central Nervous System 
Aseptic meningitis 
Cerebrovascular disease 
Demyelinating syndrome 
Headache (including migraine and benign intracranial hypertension)
Movement disorder (chorea) 
Myelopathy 
Seizure disorder 
Acute confusional state 
Anxiety disorder 
Cognitive dysfunction 
Mood disorder 
Psychosis 
Peripheral Nervous System 
Acute inflammatory demyelinating polyradiculoneuropathy (Guillain‐Barré syndrome) 
Autonomic disorder 
Mononeuropathy, single/multiplex 
Myasthenia gravis 
Neuropathy, cranial 
Plexopathy 
Polyneuropathy 
Adapted from The American College of Rheumatology nomenclature and case definitions for 
neuropsychiatric lupus syndrome. Arthritis Rheum 42:599, 1999. 
Cardiopulmonary: 
                                          Pleuritic pain (sometimes with pleural effusions) and 
pericardial pain (with or without effusion) occur in SLE. Pleurisy is more common 
than pericarditis, but they can occur together. Rare cardiac manifestations include 
Libman-Sacks endocarditis with valvular vegetations, myocarditis, and coronary 
arteritis. Pulmonary hypertension can be primary or secondary to pulmonary emboli. 
Pulmonary hypertension in lupus is usually mild, but it can progress. Interstitial 
pneumonitis, both acute and chronic, may occur. Life-threatening pulmonary 
hemorrhage is an unusual finding.   
Gastrointestinal: 
                                       Oesophageal dysmotility occurs in SLE, but is usually mild. 
Hepatomegaly and splenomegaly may occur, especially in children. Pancreatitis is a 
rare manifestation. Mesenteric vasculitis can lead to postprandial pain, abdominal 
pain, infarcts, and bowel perforation. Colitis and protein-losing enteropathy are 
extremely rare. A few SLE patients will have overlap with primary biliary cirrhosis or 
autoimmune hepatitis. About one-third of SLE patients have a mild elevation of liver 
function tests. 
Constitutional: 
                                          Many SLE patients have low-grade fever (a few with 
temperatures higher than 39°C). Weight loss can occur, especially at presentation, 
but is rare. Lymphadenopathy can be found, usually small and symmetric. An acute 
fatigue can occur with lupus flares. Chronic fatigue is common, often as part of 
fibromyalgia, which occurs in as many as 30% of SLE patients. 
Hematologic: 
                                    Anemia is very common in SLE but is multifactorial. The classic 
anaemia, a hemolytic anaemia with increased reticulocyte count, direct Coombs test, 
and low haptoglobin, is not the most common. Anemia of chronic disease is the most 
common finding. Anemia may also be due to iron deficiency, renal insufficiency or 
failure, or to sickle cell (or trait) and thalassemia. Leukopenia is common but usually 
mild. It is rare for the white blood cell count to be below 1000/L. Lymphopenia is 
frequent (glucocorticoids also cause lymphopenia). Neutropenia can occur but is 
rare. Mild or profound thrombocytopenia can occur. Antiphospholipid antibodies are 
also associated with thrombocytopenia. The partial thromboplastin time may be 
prolonged due to a lupus anticoagulant. The erythrocyte sedimentation rate or C-
reactive protein level may be elevated. The erythrocyte sedimentation rate and C-
reactive protein do not correlate with or predict clinical disease activity. 
                                         Lymphadenopathy occurs in approximately 40% of patients 
usually at the onset of disease or during disease flares. The nodes are typically soft, 
nontender, and discrete, and usually are detected in the cervical, axillary, and 
inguinal area. Biopsy specimens reveal areas of follicular hyperplasia and necrosis.[16] 
The appearance of hematoxylin bodies is highly suggestive of SLE, but is uncommon. 
                                           Splenomegaly occurs in 10% to 45% of patients, particularly 
during active disease, and is not associated with cytopenias. Periarterial fibrosis, or 
“onionskin” lesions, in the spleen has been considered pathognomonic of SLE and is 
thought to represent healed vasculitis. Splenic atrophy and functional hyposplenism 
also have been reported in SLE and may predispose to severe septic complications.[17]  
 
                            Laboratory Findings in Systemic Lupus Erythematosus: 
 
 
Test  Typical  Unusual 
Hematologic  Anemia of chronic disease  Neutropenia 
  Hemolytic anaemia with elevated reticulocyte 
count 
 
  Leukopenia   
  Thrombocytopenia   
  Elevated erythrocyte sedimentation rate or C‐
reactive protein 
 
  Prolonged partial thromboplastin time, DR VVT, 
or other tests for lupus anticoagulant 
 
Comprehensive 
metabolic panel 
Elevated blood urea nitrogen or creatinine  Elevated liver 
function tests 
Other chemistry  Elevated creatine kinase or aldolase   
  Elevated homocysteine   
  Elevated cholesterol   
Urinalysis  Proteinuria   
  Red blood cells or red blood cell casts   
 
 
 
Imaging Studies: 
                                 Magnetic resonance imaging of the brain is preferred over 
computed tomography in the evaluation of central nervous system lupus. The most 
common finding is small white matter lesions, which may represent immune 
complex deposition. Cerebral atrophy can also occur. 
                                Magnetic resonance imaging of the hip is the best way to find 
osteonecrosis at an early stage, when it may be ameliorated by core decompression. 
Bone scan can detect subclinical involvement of other sites. 
Special Tests: 
Autoantibodies: 
                               Most (96% or more) SLE patients have a positive antinuclear 
antibody (ANA) test result. Because up to 20% of healthy young women also have a 
positive ANA, the presence of an ANA alone is not given much weight. Titers of 1:640 
or higher are more indicative of a connective tissue disease of some sort. Some 
autoantibodies are very specific for lupus, such as anti-dsDNA (which occurs in 
about 30%) or anti-Sm (this is an abbreviation for Smith, not smooth muscle). Other 
autoantibodies, such as anti-Ro/SS-A, anti-La/SS-B, and anti-ribonucleoprotein, 
occur in SLE but also in rheumatoid arthritis and in Sjogren syndrome. 
Antiphospholipid antibodies  are found in 10% to 40% of SLE patients during the 
course of disease. They are associated with an increased risk of thrombosis and 
pregnancy loss. A recently identified autoantibody, anti-SR, has received Food and 
Drug Administration approval for testing in SLE. 
                   
                             AUTOANTIBODIES AND CLINICAL FEATURES 
 
Complement: 
                         Reduction in the complement components C3 and C4 or in total 
hemolytic complement occurs frequently, but is not specific for lupus. 
Special Examination: 
                         A skin biopsy with immunofluorescence is helpful in the diagnosis of 
SLE cutaneous lesions. 
                         In patients with nephritis, a renal biopsy can determine the ISN 
subtype (mesangial, focal proliferative, diffuse proliferative, or membranous) and 
give information on both activity and chronicity (damage). 
                         In patients with neuropathy, a nerve conduction study and biopsy may 
be necessary to document vasculitis. An electromyelogram and muscle biopsy may be 
needed in the evaluation of myositis. 
 
 
       REVIEW OF OCULAR MANIFESTATIONS IN SLE 
                                                    SLE can affect the eye, optic nerve, other areas in the 
central nervous system (CNS), and ocular adnexa. Severe vision loss is often the 
result of vaso-occlusive insults to the retina or optic nerve. Ocular manifestations 
occur in approximately 15% of patients with SLE. Children with SLE may have a 
higher risk (~35%) of ocular manifestations. Ophthalmic problems may be an 
important part of overall disease activity, and are thus featured in the latest version 
of the British Isles Lupus Assessment Group index of disease activity (BILAG 
2004)[18]. 
   
ANTERIOR SEGMENT  MANIFESTATIONS 
 
POSTERIOR & NEURO MANIFESTATIONS 
Keratoconjunctivitis Sicca (KCS) 
 
Vascular complications/retinopathy 
Uveitis  Vein Occlusions 
Generalized orbital inflammation  Non‐specific Retinopathy 
Acute proptosis  Neuro‐ophthalmic complications 
Lid edema  Retrobulbar optic neuritis (RON) 
 
Limited ocular motility  Anterior ischemic optic neuropathy 
Episcleritis/scleritis  Acute papillitis 
 
PATHOPHYSIOLOGY OF OCULAR DISEASE: 
                                SLE may cause ocular disease by a number of mechanisms 
including immune complex deposition and other antibody related mechanisms, 
vasculitis and thrombosis. Immune complex deposition has been identified in blood 
vessels of the conjunctiva, retina, choroid, sclera, ciliary body, in the basement 
membranes of the ciliary body and cornea, in the peripheral nerves of the ciliary 
body and conjunctiva [19]. Antibody dependent cytotoxicity may cause retinal cell 
death and demyelination of the optic nerve. Pathogenic circulating antibodies 
include anti-phospholipid antibodies (APA) and antineuronal antibodies. Similar 
mechanisms centred on the lacrimal gland may result in secondary Sjogren’s 
syndrome with consequent dry eyes (keratoconjunctivitis sicca) due to inadequate 
tear production; this is in marked contrast to most cases of dry eyes in the general 
population where it is primarily a problem of disturbance of the lipid layer of the tear 
film resulting in increased tear evaporation. 
PRESENTATION OF OPHTHALMIC DISEASE: 
                                         Ocular manifestations in SLE are fairly common, potentially 
sight threatening and may be the presenting feature of their disease[20]. SLE may 
affect almost any part of the eye and visual pathway. Additionally drugs used in the 
treatment of SLE may cause ocular problems such as cataract or retinopathy. The 
patient will usually be aware that there is an ‘eye problem’, and will report it to their 
rheumatologist (or General Practitioner). It is therefore important that the 
implications of these symptoms are recognized and appropriate help is sought. In 
general terms, pain (often accompanied by visible inflammation or redness) usually 
indicates significant external/anterior segment disease, whereas problems with 
vision (blurring, distortion, double vision usually indicates posterior segment/neuro-
ophthalmic disease. All such complaints warrant urgent referral to an 
ophthalmologist for more detailed assessment. 
 
 
 
 
                                                          CAUSES OF RED EYE IN SLE 
 
 
CAUSES OF LOSS OF VISION IN SLE: 
 
                                        Keratoconjunctivitis sicca, or dry eye, is a common ocular 
manifestation of SLE[21] . Secondary Sjogren’s syndrome is also associated with the 
disease[22] . In a study by Jensen et al. [23] 60% of 20 patients with SLE reported at 
least one symptom of dry eye. Typical findings on ophthalmic examination include 
corneal epitheliopathy, abnormal tear film, and decreased tear production. More 
significant manifestations such as filamentary keratitis, corneal scarring, or 
ulceration can occur. Typical treatment options include lubricating drops and 
ointments, punctual occlusion, and topical cyclosporine drops. Other corneal 
manifestations of SLE, including peripheral ulcerative keratitis, interstitial keratitis, 
and keratoendotheliitis with corneal edema, are uncommon[24] . 
                                  The retina is a common site of ocular involvement in patients with 
lupus. The proportion of patients with SLE who manifest retinal involvement varies 
depending on the population studied and ranges from 3% in well controlled patients 
to 29% in patients with more active systemic disease[25-30] . Retinal vascular changes 
are a significant ophthalmic finding, as they appear to correlate to the degree of 
systemic disease activity[27] . In one prospective study by Stafford-Brady et al.[26] , 
88% of patients with retinopathy had active systemic disease, and 73% had active 
CNS involvement. Furthermore, these authors showed that patients with retinopathy 
had a lower overall rate of survival during their follow-up interval as compared with 
individuals without retinopathy. The retinal microangiopathy associated with SLE is 
thought to result from immune complex-mediated vascular injury and microvascular 
thrombosis. Antiphospholipid antibodies may play a critical role in some patients. In 
a study by Montehermoso et al. [25] antiphospholipid antibodies were found in 77% of 
patients with lupus related retinal or optic nerve disease, compared with only 29% of 
SLE patients without such ocular involvement. Retinal findings most commonly 
associated with lupus are cotton wool spots and intraretinal hemorrhages[31] . 
                                          Other retinal manifestations may include microaneurysms, 
vascular tortuosity, arteriolar narrowing, retinal edema, or exudates[28-30] . 
Fluorescein angiography may be helpful in patient evaluation[30] . Most patients with 
mild retinopathy are at low risk for vision loss[26,30]. 
                                          In contrast, severe vaso-occlusive retinopathy is a rare but 
well described entity that is associated with widespread retinal capillary 
nonperfusion, multiple branch retinal artery occlusions, ocular neovascularization, 
vitreous hemorrhage, and significant resultant visual loss[32,33] . A study by Jabs et 
al.[31]  showed that 55% of eyes with severe retinal vaso-occlusive disease suffered 
vision loss, often to a visual acuity of worse than 20/200. The authors also found that 
CNS involvement by lupus was a frequent association in patients with such marked 
retinal vascular changes. Central retinal vein or artery occlusions can also occur, 
either independently or together, and may be unilateral or bilateral[34]. 
                                            Systemic immunosuppression with corticosteroids and 
steroid-sparing agents are the primary treatment modalities for patients with 
significant retinal disease. Intravenous corticosteroid pulse therapy may be needed 
in acute settings to control severe retinal involvement. Patients with significant vaso-
occlusive disease or antiphospholipid antibodies may benefit from treatment with 
antiplatelet agents such as aspirin or through anticoagulation with warfarin[32] . 
Plasmapheresis has been used together with immunosuppressive agents in managing 
patients with severe retinal vasculitis . Panretinal photocoagulation and vitrectomy 
surgery should be used as appropriate to control neovascularization and vitreous 
hemorrhage in order to limit further vision loss and other complications of ocular 
ischemia. 
                                          Choroidopathy, uveal effusions, and serous retinal 
detachment may occasionally occur in patients with SLE[35]. Significant uveal 
effusions may also lead to secondary angle-closure glaucoma[36]. Nguyen et al.[35]  
reported on a total of 28 patients with lupus choroidopathy, all of whom had active 
systemic vascular disease. Choroidopathy resolved in 82% of patients once systemic 
control of the disease was achieved. 
                                          SLE can have many neuroophthalmic manifestations. Optic 
nerve involvement occurs in approximately 1% of patients with SLE[37]. Optic neuritis 
and neuropathy can potentially lead to severe loss of vision[38-39]. Optic neuritis may 
occur together with transverse myelitis in patients with SLE, thus raising clinical 
suspicion for demyelinating diseases such as multiple sclerosis[39] . Ischemic optic 
neuropathy[40]  and chiasmopathy[41]  have also been described. Optic nerve 
dysfunction can be the initial manifestation of systemic disease in some patients. 
Patients may present with painless vision loss, impaired colour vision, visual field 
defects, pupillary abnormalities, and may have optic disc edema or pallor on 
examination. 
                                            Lin et al.[42]  described eight patients with SLE-associated 
optic neuritis. Eighty-seven percent of these patients had visual acuities worse than 
20/200 at onset, and final visual outcomes were highly variable despite 
corticosteroid pulse therapy followed by a tapering oral corticosteroid course. The 
authors emphasize the importance of differentiating SLE-associated optic neuritis 
from idiopathic optic neuritis. Patients with SLE may experience severe visual 
impairment with long-term dependence on immunosuppressive therapy. Treatment 
options for optic nerve disease include systemic corticosteroids and 
immunosuppressives such as cyclophosphamide and methotrexate[41]. Other neuro-
ophthalmic manifestations are less common. Eye movement abnormalities[43] , 
intranuclear ophthalmoplegia[44] , and retrochiasmal involvement[45]  leading to 
visual hallucinations and vision loss have been described. 
                                         Episcleritis, scleritis, and conjunctivitis have been reported in 
association with SLE[46]. Scleritis, in particular, can cause significant ocular 
morbidity and can be associated with active systemic disease. Pathologic studies 
using immunohistochemical stains in conjunctival biopsy specimens have implicated 
an underlying immune-complex mechanism[47]. 
                                       Lupus may affect the ocular adnexal structures as well. 
Cutaneous involvement may lead to a discoid-type, scaly rash on the eyelids[48]. The 
clinical picture may resemble chronic blepharitis or eczema[49]. Lupus should be 
considered in the differential diagnosis of chronic blepharitis that fails to respond to 
traditional treatment measures and skin biopsy can be performed to confirm the 
diagnosis. Immunohistochemical stains typically demonstrate immunoglobulin 
deposition at the dermoepidermal junction[48]. Mistaken diagnosis may lead to eyelid 
margin deformities and may delay the diagnosis of systemic lupus[50]. Cutaneous 
involvement from SLE typically responds well to systemic hydroxychloroquine[48,49]. 
Protection from excessive sunlight should be emphasized. Local corticosteroids, 
including intralesional triamcinolone in some cases, may be of benefit as well[51]. 
                                        Orbital disease is a rare presentation of SLE. Orbital 
inflammation, infarction, myositis, panniculitis, proptosis, and periorbital edema 
have been described[52]. A tissue biopsy and systemic evaluation may be necessary to 
confirm the diagnosis and to exclude other diseases such as thyroid-related 
orbitopathy, other inflammatory conditions, infection, and neoplastic processes. 
OPHTHALMIC DISEASE AND THE ROLE OF ANTI-PHOSPHOLIPID 
ANTIBODIES: 
                                         The presence of APA is associated with vaso-occlusive disease 
(both retinal and CNS) in SLE[53]. Interestingly retinal vascular occlusions and even a 
similar retinopathy may also be seen in primary anti-phospholipid syndrome. In 
general, the presence of APA is linked to focal thrombotic events that may prompt 
the use of anti-coagulation or low dose aspirin in addition to immunosuppression. 
 
OPHTHALMIC DISEASE IN DRUG INDUCED LUPUS: 
                                    Ocular complications are rare in drug-induced lupus, although 
retinal vasculitis and occlusive disease have been reported in hydralazine and 
procainamide induced lupus syndrome. 
OPHTHALMIC DISEASE AS A SIDE-EFFECT OF TREATMENT: 
                                    Ophthalmic side effects and disease can also result from the 
medications used to treat SLE. Both topical and systemic corticosteroids may 
accelerate cataract formation and may cause steroid-induced glaucoma. Central 
serous retinopathy is also associated with corticosteroid use. Other 
immunosuppressive agents are usually more costly, have their own side-effects and 
need careful monitoring. Overwhelming septic cavernous sinus thrombosis has been 
reported after a combination of high dose steroid and intravenous cyclophosphamide 
therapy for lupus nephritis[54].  
                                        The aminoquinolones, chloroquine and, to a lesser extent, 
hydroxychloroquine can cause reversible visually insignificant changes in the cornea 
(vortex keratopathy) and, more importantly, an irreversible sight-threatening 
maculopathy. Initial changes are subtle (loss of foveal reflex and a fine granular 
appearance) and  often asymptomatic, but can progress to a ‘bull’s eye’ maculopathy 
and even generalized atrophy of the retina and optic nerve[55]. This retinopathy may 
continue to progress despite cessation of the drug. Although both drugs can cause 
identical changes the risks are much lower with hydroxychloroquine, particularly at 
recommended doses of up to 6.5 mg/kg/day[56,57]. Below this level, 
hydroxychloroquine, toxicity is extremely rare. One prospective cohort study of 400 
patients receiving long-term hydroxycholoroquine of up to 6.5 mg/kg/day found only 
two patients to be affected, in both cases only after 6 yrs of treatment[58]. Indeed 
Lee[59]  estimated that at these recommended levels there have been only 20 affected 
cases in over a million patients receiving the drug; all 20 cases had been taking the 
drug for over 5 yrs. 
                                                           In the UK, the Royal College of Ophthalmologists have 
advised that the prescribing rheumatologist should carry out the baseline assessment 
of lean body weight (if overweight), renal and liver function, asking about any visual 
impairment which is not corrected by glasses and testing reading vision[56]. Any 
apparent visual impairment or eye disease should be first confirmed by an 
optometrist, and then referred on to the local ophthalmologist before starting 
treatment. If visual problems occur once treatment has started, patients should be 
advised to stop treatment, attend their optometrist and seek advice from the 
prescribing physician who would refer on to the ophthalmologist. Annual evaluation 
should be by the prescribing rheumatologist and includes enquiry about visual 
symptoms and measuring reading acuity[56]. In the USA, screening by an 
ophthalmologist is recommended for those patients on hydroxychloroquine who are 
at higher risk: dose >6.5 mg/kg/day, duration of treatment >5 yrs, renal or hepatic 
disease, pre-existing retinal disease or age >60 yrs[57]. Chloroquine has a less clear 
safety profile and should be avoided where possible. All patients taking chloroquine 
should have regular ophthalmic examination according to locally arranged protocol.  
                                                       Chloroquine and hydroxychloroquine are well known to 
cause sight-threatening macular disease, leading to decreased vision, abnormal 
colour vision,  reproducible and permanent visual field defects[60,61]. Corneal 
verticillata is a common finding in patients taking chloroquine, but this rarely affects 
vision[62]. 
                                                Thus SLE may have many ocular manifestations. A high 
clinical suspicion for lupus should be maintained as ocular involvement may be the 
initial presentation of systemic disease and may parallel overall disease activity. 
Significant ocular morbidity and vision loss may occur, and close monitoring and 
appropriate local and systemic treatments are necessary. As our knowledge of the 
underlying immunologic mechanisms of SLE improves, newer biologic agents may 
play an increasingly important therapeutic role. Collaboration with primary care 
providers and other medical subspecialists may be necessary to best manage the 
disease. 
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                                      AIM 
 
The aim of the work was to assess 
1] the frequency of eye changes among patients with SLE,  
2]  the association between anti-phospholipid antibodies and ocular lesions, 
3] the correlation of the ocular manifestations with disease activity, 
4] the relationship between the presence of circulating autoantibodies and eye 
changes. 
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              MATERIALS AND METHODS 
STUDY DESIGN:              Prospective study 
STUDY CENTRE:             Department of Rheumatology, 
                                                  Madras Medical College& Government General Hospital, 
                                                   Chennai -3. 
STUDY PERIOD:                March -  2009 to March – 2010 
STUDY POPULATION: Consecutive cases of lupus patients who                         
are attending the Department of Rheumatology,  GGH Chennai. 
STUDY SAMPLE:                110 patients. 
INCLUSION CRITERIA:  
1] Patients who satisfied the 1997 Revised Criteria for the Classification of Systemic
Lupus Erythematosus (SLE) 
2]AGE: All age group  
3]SEX: Both genders 
EXCLUSION CRITERIA: 
1] Patients who do not satisfy the 1997 Revised Criteria for the Classification of 
Systemic Lupus Erythematosus (SLE) 
2] Patients with overlap syndrome 
STUDY PROCEDURE: 
ETHICAL CONSIDERATION: 
                                       The study was commenced after obtaining approval from the 
Institutional Ethical Committee. Patients with SLE attending Rheumatology OPD or 
got admitted in Rheumatology ward , Government General Hospital were included in 
this study and were explained about the purpose of the study. Written informed 
consent was obtained from those who were willing to participate in the study in the 
prescribed format in regional language. Left thumb impression was obtained from 
those patients who are illiterates. 
SCREENING: 
                                        Apart from age and sex, detailed medical history including 
mode of onset, duration of illness, constitutional, mucocutaneous, musculoskeletal 
and symptoms pertaining to the ocular involvement i.e. dry eyes, red eyes, swelling 
over eye lids, decreased visual acuity, floaters, ocular pain, headaches, itching, 
flashes, watering, double vision (diplopia) and relevant history of other organ 
involvement was obtained. History of recurrent abortion if relevant, venous or 
arterial thrombosis were noted. All patients were questioned for hypertension, 
diabetes, CAHD and pulmonary tuberculosis. Alcohol and smoking habits were also 
enquired. Detailed clinical examination was done in all patients. 
                                     Laboratory investigations including complete blood count, urine 
analysis, blood sugar, urea, creatinine, serum electrolytes, liver function tests, muscle 
enzyme analysis and fasting lipid profile were done for all patients. 
IMMUNOLOGICAL INVESTIGATIONS: 
 
                                   C-reactive protein was done by latex agglutination method, ANA 
by either ELISA [Cal Biotech] or indirect immunofluorescence method, Anti-ds DNA 
by ELISA [Warpole lab] or Crithidia test and aCL IgG and IgM by ELISA method 
were done in all patients. 
PRINCIPLE: 
 
                                    Microwells are pre-coated with purified antigen/antigens. The 
pre-diluted controls, together with diluted patient samples are added to the wells, 
autoantobodies recognizing one or a combination of antigens bind during the first 
incubation. After washing the wells to remove all unbound proteins, peroxidase 
labelled rabbit anti-human IgG conjugate is added. The conjugate binds to the 
captured human autoantibody and the excess unbound conjugate is removed by a 
further wash step. The bound conjugate is visualised with 3,3’,5,5’ 
tetramethylbenzidine(TMB) substrate which gives a blue reaction product, the 
intensity of which is proportional to the concentration of autoantibody in the sample. 
Acid is added to each well to stop the reaction. This produces a yellow end point 
colour, which is read at 450nm by using ELISA reader. 
Cut-off value for ANA:  
 
ANA result Interpretation 
≤0.90 Negative 
0.91 to 1.09 Equivocal 
≥1.10 Positive 
 
 Cut-off value for Anti-ds DNA: 
 
                                              
            Interpretation 
≤0.90 Negative  
0.91 to 1.09 Equivocal 
≥1.10 Positive  
 
Interpretation of results for aCL IgG and IgM antibodies 
 
aCL IgG aCL IgM 
<10 GPL units/mL Negative <15 MPL units/mL Negative 
10 – 15 GPL 
units/mL 
Borderline 
Positive 
15 – 20 MPL 
units/mL 
Borderline 
Positive 
>15 – 80 GPL 
units/mL 
Moderate 
Positive 
>20 – 80 MPL 
units/mL 
Moderate 
Positive 
>80 GPL units/mL High Positive >80 MPL units/mL High Positive 
 
                                         The complement levels were measured using Single Radial 
Immune Diffusion plates. The procedure consists of immunoprecipitation in agarose 
gel between an antigen and its homologous antibody. It is performed by 
incorporating the anti C3 and anti C4 antibodies uniformly throughout a layer of 
agarose gel and antigen is added into the wells duly punched in the gel. Antigen 
diffuses radially out of the well into the surrounding gel and a visible ring of sharp 
precipitation forms where the antigen and antibody reacted in the zone of 
equivalence. A quantitative relationship does exist between ring diameters and 
complement concentration.  The reference value for C3 is 80 – 160 mg/dl and for C4 
is           20 – 40 mg/dl.  
                                        Lupus Anticoagulant Study including activated partial 
prothrombin time, dilute Russel Viper venom test and Kaolin clotting time were 
done.  
OPHTHALMIC EVALUATION: 
 
                                        All the patients underwent detailed ophthalmic examination at 
Government Ophthalmic Hospital And Regional Institute Of Ophthalmology, 
Chennai. Each eye was assessed individually. 
1] VISUAL ACUITY: 
 
                                         The assessment of distant and near visual acuity was done by 
asking the patient to cover one of the eyes with a cardboard or with the palm of his 
hand.  
DISTANT VISUAL ACUITY: 
                                       Distant visual acuity was more accurately recorded with 
Snellen’s chart. It is read at six metres, with the letters diminishing in size from 
above. The patient has normal vision if he is able to read the line of letters designated 
as 6/6 at or near the bottom of the chart. The scale for decreasing distant visual 
acuity is 6/9, 6/12 (industrial vision), 6/18, 6/24, 6/36 and 6/60 (legal blindness in 
some countries). 
                                                               If the patient is unable to read the letters, he is asked to 
count the examiner’s fingers which are held a metre away. If his answers are correct, 
he has distant visual acuity of “counting fingers” at a metre. If he is unable to count 
the fingers, the examiner should move his hand in front of the patient’s eyes. The 
visual acuity is then said to be “hand movement”. If he can see only light, visual 
acuity is recorded as “perception of light”. If he cannot see any light, visual acuity is 
recorded as “no perception of light” which is total blindness. 
NEAR VISUAL ACUITY:  
                                                The common near visual acuity tests used are the Jaegar 
test and the ‘N’ chart, usually read at a distance of 30 cm. The Jaegar test is recorded 
as J1, J2, J4, J6, etc., and the ‘N’ chart as N5, N6, N8, N10, etc. Standard small 
newsprint is approximately J4 or N6. Each eye is tested in turn with the other 
covered. Middle-aged patients (presbyopic age) were tested with their reading 
glasses. 
2] VISUAL FIELDS: 
 
                                        The visual fields can be recorded approximately by using the 
confrontation test. The patient covers the eye which is not being tested with his palm 
and fixes the other at the examiner’s nose, ear or eye. A target is then brought into 
his field of vision from the side and the point at which the patient sees the object is 
noted. The eye is tested in the different meridians, usually 8. 
EXTERNAL EYE EXAMINATION: 
 
                                           This is done with good illumination from either a window or a 
bright torch. A magnifying glass facilitates examination and should be used whenever 
available. Common problems screened include drooping of the upper eyelid (ptosis), 
lid retraction, inability to close the lids (lagophthalmos), eversion of the lid margins 
(ectropion) and inversion of lid margins (entropion). Detailed examination of the eye 
lids, conjunctiva, cornea, iris, pupils, anterior chamber and lens were done. 
 
 
 
PUPIL RESPONSE: 
 
                                       The response of light directed at one pupil in a darkened room is 
known as the direct pupillary response. The reaction of light by the fellow pupil is 
called the consensual pupillary response. If there is no pupillary reaction to light, the 
reaction to accommodation is tested by asking the patient to fix his eyes on an object 
at a distance and then to focus on another object at about 10 cm away from him. 
EXTRAOCULAR MUSCLES: 
 
                                       The extraocular muscles are examined by observing the position 
of the eyeballs with the patient looking straight ahead.  One eye may be observed to 
be turned inwards (convergent squint) or outwards (divergent squint). Occasionally, 
one of the eyes may be seen to be higher than the other (vertical squint). 
OCULAR MOVEMENTS: 
 
                                 When the extraocular muscles are severely paralysed, the restriction 
in movement is tested by asking the patient to look in 7 different directions 
(positions of gaze). 
 
 
The six cardinal positions of gaze and their corresponding primary extraocular 
muscle actions. 
OPHTHALMOSCOPY: 
                                                   The ophthalmoscope is used to observe abnormality in the 
ocular media, optic disc, retinal vessels, fundal background and the macula.  
RED REFLEX:  
                                        With the lens power of the ophthalmoscope turned to 0 and the 
ophthalmoscope held one metre away from the patient’s eye a red reflex is seen 
through the pupil. Alternatively the lens power can be turned to about +5 dioptres 
and the eye examined approximately 10 cm away. This is caused by the reflection of 
the light of the ophthalmoscope from the choroidal vessels. It appears as a bright red 
round area which is evenly lighted. Any opacity in the cornea, lens (cataract) or 
vitreous will be seen as a dark area. In retinal detachment, the reflex appears grey 
instead of red. 
FUNDUS:  
                                        Examination of the fundus is usually done with the direct 
ophthalmoscope. The refractive error in both the patient and examiner has to be 
compensated for by adjusting the lens power of the ophthalmoscope. Alternatively, 
the examiner and patient may use their glasses or contact lenses in which case no 
adjustment will be required. The patient is then instructed to look at a distant object. 
When the right fundus is examined, the ophthalmoscope is held in the right hand. 
The examiner uses his right eye to examine the patient’s right eye approaching from 
the right side. The patient’s left fundus is examined with the examiner’s left eye and 
the patient is approached from the left. It is important to get near enough so that the 
examiner’s forehead touches his own thumb which is used to lift the upper lid of the 
eye being examined. 
                                                            It is best to approach the eye from the temporal side so 
that a good view of the disc can be seen before the pupil contracts when light is shone 
on the macula. The nasal retinal vessels and the temporal retinal vessels are 
examined before the macula. Because of the extreme sensitivity of the macula to light 
which results in rapid constriction of the pupil, examination of the macula is difficult 
and usually requires a mydriatic eyedrop to dilate the pupil. 
BINOCULAR SLIT-LAMP MICROSCOPY:  
                                                The binocular slit-lamp microscope enables accurate 
observation of the eye up to a magnification of 40 times. It consists of two parts, an 
oblique light which can be adjusted to a slit and a binocular microscope. Other uses 
of the slit-lamp include examination of the retina with magnification from a Hruby 
or contact lens and checking the filtrating angle of glaucoma patients (gonioscopy). 
TONOMETRY:  
                                            A tonometer is used to measure intraocular pressure. The 
most widely used tonometer is the Goldmann Applantation Tonometer. The Schiotz 
Indentation Tonometer is less accurate but it is portable. The new non-contact 
tonometers do not require local anaesthesia. 
PERIMETRY AND SCOTOMETRY:  
                                           Perimetry gives a more exact record of the visual fields than 
the confrontation test. The ability of the patient to see a small 5 mm target on an arc 
moving into his view from the periphery at different meridians is recorded on to a 
chart. Scotometry is used to assess the central 30° part of the field of vision. It 
involves using a small 1–5 mm target on a screen (Bjerrum or Tangent screen) placed 
1 or 2 metres away and noting when the test target appears. The normal blind spot is 
found 15° lateral to the fixation point. 
 
TESTS FOR COLOUR VISION:  
                                                The Ishihara test is most commonly used for colour vision. 
It is very sensitive test. Lantern colour matches or Farnsworth Munsell 100 hue test 
are other tests for colour vision. 
REFRACTION:  
                                                 It can be objective with retinoscopy. Subjective tests are 
done with a trial frame and a set of lenses. Alternatively, the lenses may be mounted 
on a series of rotating discs (phoropter). 
SCHIRMER’S TEST: 
                                                Schirmer’s test is done to measure the quantity of tears 
produced by eyes. In Schirmer’s test a 35 mm× 5mm Whatman filter paper is used to 
measure the amount of tears that is produced over a period of 5 minutes. The strip is 
placed at the junction of middle and lateral thirds of the lower eye lid. The test is 
done under ambient light. The patient is instructed to look forward and to blink 
normally during the course of the test. 
Interpretation: 
1. Normal which is =>15 mm wetting of the paper after 5 minutes. 
2. Mild which is 14-9 mm wetting of the paper after 5 minutes. 
3. Moderate which is 8-4 mm wetting of the paper after 5 minutes. 
4. Severe which is <4 mm wetting of the paper after 5 minutes. 
                                       Ultrasonography, CT scan and Magnetic Resonance Imaging 
(MRI), Macular potential acuity, electrophysiology including electroretinography 
(ERG), electrooculography (EOG) and visual evoked response study (VER) were 
done if relevant. 
 
 
Statistical analysis: 
                                            he statistical analysis was performed using the SPSS version 
17.0. Results are presented as the mean±S.D., except for frequencies, which are 
expressed as percentages. Comparison between groups were made by means of 2-
sample t-test, and Chi square test used when appropriate. P values less than 0.05 
were considered significant. 
 
 
 
        
 
 
 
 
 
 
 
 
  
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
                           RESULTS 
                                            The present study consisted of 110 SLE patients.  There 
were 11 males and 99 females in the study group [Fig. 1]. The age of the patients 
varied from 9 years to 65 years [Fig. 2]. The mean age of the patients was 25.9±9.2 
years. The mean duration of disease was 29±30.8 months with disease onset in the 
second or third decade being the commonest. 12[10.9%] patients had childhood 
onset of the disease [Fig. 3] with mean age being 13±2.13 years. The mean disease 
duration in childhood onset was 12.25±7.84 months. 
                                                                          TABLE 1 
                        Cross tabulation: Disease duration Vs Ophthalmic manifestation 
Disease 
duration 
Ophthalmic status Total 
Normal Abnormal 
≤3 yrs 57 67.06% 28 32.94% 85 
>3 yrs 13 52% 12 48% 25 
Total 70  40  110 
 
Chi squared equals 1.893 with 1 degree of freedom.  
The two-tailed P value equals 0.1689. This implies that the ophthalmic involvement 
is  independent of disease duration in SLE patients. 
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                                                                      TABLE 2 
                                             SEX WISE DISTRIBUTION OF PATIENTS 
Group SLE Childhood SLE SLE with APS cSLE with APS 
Male Female Male Female Male Female Male Female 
Number 9 67 1 6 Nil 22 1 4 
% 8.18% 60.9% 0.9% 5.45% Nil 20% 0.9% 3.63% 
 
                                           Out of the 110 patients 23 patients[20.9%] had ocular 
complaints remaining 87 patients[79.1%] had no ocular symptoms. The common 
ocular complaints were blurring of vision – 12 patients[10.9%], dry eyes – 3 
patients[2.7%], red eyes – 3 patients[2.7%], swelling over eye lid – 2 patients[1.8%] , 
itching, eye discharge and  restriction of eye movements – each 1 
patient[0.9%].Refractive error was seen in 11[10%] of patients.                                            
                                             Ocular abnormalities were seen in 40 patients [36.4%]. 70 
patients [63.6%] had no ocular abnormalities.  Among the 40 patients with ocular 
abnormality 14 patients [35%] were found to have associated APS. Among the 40 
patients 36 patients [90%] were females,  1 patient[2.5%] was male and 3 
patients[7.5%] had childhood onset of disease. The most common abnormalities 
were dry eyes [11.8%], retinal vasculitis[3.6%], posterior subcapsular cataract[3.6%] 
and cotton wool spots in fundus [2.7%]. The other ocular abnormalities found were 
post neuritic optic atrophy[0.9%], filamentary keratitis[0.9%], subconjunctival 
hemorrhage[1.8%], hypertensive retinopathy [1.8%], blepharitis [0.9%], macular 
edema [1.8%], meibonitis[0.9%], conjunctivitis[0.9%], retinal detachment[0.9%], 
complicated cataract[0.9%], fibrovascular proliferative uveitis[0.9%], anterior 
uveitis[0.9%], CRAO[0.9%], chloroquine maculopathy[1.8%], hordeolum 
internum[0.9%], herpes zoster ophthalmicus[0.9%], dacryocystitis[0.9%], lateral 
rectus palsy[0.9%], multiple punctate erosion of cornea[0.9%] and cherry red 
spot[0.9%]. 
                                                               TABLE 3 
                 OCULAR MANIFESTATIONS IN SLE AND SLE WITH APS PATIENTS 
s.n
o 
Ocular 
manifestation 
SLE 
[N=83] 
% SLE 
WITH 
APS 
[N=27] 
% Total no. of 
patients 
[N=110] 
% 
1 Post neuritic 
optic atrophy 
  1 3.7% 1 0.9% 
2 Dry eyes 9 10.8
% 
4 14.8% 13 11.8
% 
3 Filamentary 
keratitis 
1 1.2%   1 0.9% 
4 SCH 1 1.2% 1 3.7% 2 1.8% 
5 Hypertensive 
retinopathy 
  2 7.4% 2 1.8% 
6 Cotton wool 
spots 
3 3.6
% 
  3 2.7% 
7 Retinal 
vasculitis 
3 3.6
% 
1 3.7% 4 3.6% 
8 Blepharitis 1 1.2%   1 0.9% 
9 Macular 
edema 
2 2.4
% 
  2 1.8% 
10 Meibonitis 1 1.2%   1 0.9% 
11 Conjunctivitis 1 1.2%   1 0.9% 
12 Retinal 
detachment 
  1 3.7% 1 0.9% 
13 Complicated 
cataract 
  1 3.7% 1 0.9% 
14 Fibrovascular 
proliferative 
panuveitis 
  1 3.7% 1 0.9% 
15 Anterior 
uveitis 
1 1.2%   1 0.9% 
16 Posterior 
subcapsular 
cataract 
2 2.4
% 
2 7.4% 4 3.6% 
17 CRAO 1 1.2%   1 0.9% 
18 Chloroquine 
maculopathy 
2 2.4
% 
  2 1.8% 
19 Hordeolum 
internum 
1 1.2%   1 0.9% 
20 Herpes Zoster 
Ophthalmicus 
1 1.2%   1 0.9% 
21 Dacryocystitis 1 1.2%   1 0.9% 
22 Lateral rectus 
palsy 
1 1.2%   1 0.9% 
23 Multiple 
Corneal 
erosion 
1 1.2%   1 0.9% 
24 Cherry red 
spots 
1 1.2%   1 0.9% 
25 Vitreous 
strands 
  1 3.7% 1 0.9% 
26 Corneal 
opacity 
  1 3.7% 1 0.9% 
 
                                                               
                                                                                
                                                Only one patient had ocular manifestation as the first sign of 
SLE. One SLE patient with APS had CRAO. She was detected to have LAC  and found 
to have aCL positivity. Another patient with optic atrophy had LAC and aCL 
positivity. One patient presented with features of Steven Johnson syndrome like 
picture and was found to have  exudative retinal detachment of  both eyes, 
complicated cataract of left eye and  fibrovascular proliferative panuveitis of right eye 
with ANA and aCL positivity. Cystoid macular edema of both eyes was seen in one 
patient with SLE. No patient in our study had cavernous sinus thrombosis. 4 SLE 
patients with APS [14.8%] had dry eyes compared with 9 patients [10.8%] with SLE. 
2 SLE patients with APS [7.4%] had  hypertensive retinopathy. 
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TABLE 4 
                                 COMPARISON OF DEMOGRAPHIC AND CLINICAL PARAMETERS‐ 
                                      OCULAR INVOLVEMENT VS WITHOUT OCULAR INVOLVEMENT 
s.
n
o 
Parameters SLE with 
ocular 
involvement 
[N=40] 
% SLE without 
ocular 
involvement 
[N=70] 
% T-
Value 
P-
Value 
1 Age in yrs 
[mean±SD] 
27.38±10.52  25.07±8.35  1.265
8 
NS 
2 M:F 1:39  10:60    
3 Duration of disease 
in months 
[mean±SD] 
33.33±25.13  26.97±33.45  1.044
2 
NS 
4 Recurrent 
abortions [no. of 
patients] 
5 12.5
% 
2 2.8
% 
1.993
0 
0.046
3 
5 Gangrene/DVT 3 7.5% 4 5.7
% 
0.369
1 
NS 
6 Hypertension 9 22.5
% 
11 15.7
% 
0.887
6 
NS 
7 Neurological 
manifestation[no. 
of patients] 
10 25% 10 14.3
% 
1.4015 NS 
P significant < 0.05. 
                                                 The analysis in the Tables 4 & 5 show that there exists no 
statistically significant difference between SLE patients with ocular involvement Vs 
without Ocular involvement  in demographic, clinical and laboratory parameters 
except for recurrent abortions, thrombocytopenia, Anti-dsDNA positivity, aCL 
positivity, low complement levels and SLEDAI score which were significantly higher 
in the former group. 
 
                                                                          
                                                                             TABLE 5 
         Comparison of lab parameters ‐ Ocular involvement Vs without ocular involvement 
s.
n
o 
Parameter SLE with 
ocular 
involvement 
[N=40] 
% SLE without 
ocular 
involvement 
[N=70] 
% T-
value 
P-
value 
1 Hb in gms 
[mean±S.D] 
9.66±1.37  9.97±1.59  1.032
9 
NS 
Anaemia 
Hb<10gm [no. of 
patients] 
20 50% 27 38.57
% 
1.165
6 
NS 
2 Platelets in 
lakhs/cumm 
[mean±S.D] 
1.73±0.69  1.75±0.63  0.154
7 
NS 
Thrombocytopeni
a < 1lakh/cumm 
[no. of patients] 
0 0 9 12.85
% 
2.366
7 
0.017
9 
3 ESR in mm/hr 
[mean±S.D] 
62.42±35.34  54.73±29.94  1.212
6 
NS 
4 CRP positivity [no. 
of pts] 
21 52.5
% 
39 55.7
% 
0.325
7 
NS 
5 Anti – dsDNA [no. 
of pts] 
28 70% 31 44.2
8% 
2.601
6 
0.009
3 
6 aCL positivity [no. 
of pts] 
14 35% 12 17.14
% 
2.120
6 
0.034
0 
7 LAC study 
detected  [no. of 
pts] 
6 15% 7 10% 0.781
4 
NS 
8 Low complement 
[n0. Of patients] 
25 62.5
% 
27 38.57
% 
2.418
1 
0.015
6 
9 SLEDAI score 
[mean±S.D] 
28.05±10.19  22.62±9.34  2.837
3 
0.005
4 
P significant < 0.05. 
                                                            
                                                                        TABLE 6 
                 Comparison of demographic and clinical parameters ‐   
                                              aCL positive Vs aCL negative patients 
s.
n
o 
Parameter SLE with 
aCL 
positivity 
[N=26] 
% SLE with 
aCL 
negativity 
[N=84] 
% T-
value 
P-
value 
1 Age in yrs 
[mean±S.D] 
24.03±8.18  26.48±9.48  1.1872 NS 
2 M:F 1:25  10:74    
3 Duration of 
disease in 
months 
[mean±S.D] 
29.92±24.
43 
 28.79±31.0
6 
 0.169
8 
NS 
4 Recurrent 
abortion[no. of 
patients] 
4 15.38
% 
3 3.57% 2.1564 0.0311 
5 Gangrene/DVT 2 7.69% 5 5.95% 0.317
6 
NS 
6 Hypertension 3 11.53
% 
17 20.23
% 
1.005
0 
NS 
7 Ocular 
manifestation 
14 53.84
% 
26 30.95
% 
2.120
6 
0.034
0 
8 Neurological 
manifestation 
7 26.92
% 
13 15.47% 1.322
4 
NS 
P significant < 0.05. 
                                              In Tables 6 & 7 – comparison of demographic, clinical 
parameters and SLEDAI score between SLE patients with aCL positivity Vs aCL 
negativity show that recurrent abortions, ocular manifestations and LAC study were 
significantly higher in the former group. 
                                                             
                                                                     TABLE 7 
                   Comparison of lab parameters – aCL positive Vs aCL negative patients 
s.
n
o 
Parameters SLE aCL 
positivity 
[N=26] 
% SLE with 
aCL 
negativity 
[N=84] 
% T-
value 
P-value 
1 Hb in gms 
[mean±S.D] 
10.28±1.1
4 
 9.75±1.60  1.568
1 
NS 
Anaemia 
<10gms [no. of 
patients] 
9 34.61
% 
38 45.23
% 
0.956
8 
NS 
2 Platelets in 
lakhs/cumm 
[mean±S.D] 
1.62±0.43  1.78±0.70  1.100
9 
NS 
Thrombocytopen
ia <1 lakh 
/cumm [no. of 
patients] 
1 3.84% 8 9.52% 0.923
0 
NS 
3 ESR in mm/hr 
[mean±S.D] 
50.19±29.
91 
 59.69±32.
90 
 1.313
3 
NS 
4  CRP positivity 
[no. of patients] 
17 65.38
% 
43 51.90
% 
1.270
2 
NS 
5 Anti-dsDNA 
positivity  [no. of 
patients] 
11 42.30
% 
48 57.14
% 
1.325
6 
NS 
6 LAC study 
detected[no. of 
patients] 
12 46.15
% 
1 1.19% 6.206
2 
0.000000
05 
7 Low 
complement [no. 
of patients] 
14 53.84
% 
38 45.24
% 
0.768
3 
NS 
8 Ocular 
manifestation 
[no. of patients] 
14 53.84
% 
26 30.95
% 
2.120
6 
0.0340 
9 SLEDAI score 
[mean±S.D] 
27.15±12.
63 
 23.80±8.9
2 
 1.507
3 
NS 
P significant < 0.05. 
                                                            
                                                                        TABLE 8 
             Comparison of demographic and clinical parameters –  
                                                  LAC detected Vs LAC not detected patients 
s.
n
o 
Parameters LAC 
detected 
[N=13] 
% LAC not 
detected 
[N=97] 
% T-
value 
P-
value 
1 Age in yrs 
[mean±S.D] 
24.46±7.2
5 
 26.10±9.46  0.600
9 
NS 
2 M:F 1:12  10:87    
3 Duration of 
disease in 
months 
[mean±S.D] 
24.46±18.
24 
 29.92±32.0
3 
 0.600
1 
NS 
4 Recurrent 
abortions [no. of 
patients] 
3 23.07
% 
4 4.1% 2.628 0.008
6 
5 Gangrene/DVT 
[no.of patients] 
1 7.69% 6 6.18% 0.209
0 
NS 
6 Hypertension 
[no.of patients] 
1 7.69% 19 19.58
% 
1.0442 NS 
7 Ocular 
manifestation 
[no.of patients] 
6 46.15
% 
34 35.05
% 
0.7814 NS 
8 Neurological 
manifestation 
[no.of patients] 
2 15.38
% 
18 18.55
% 
0.2785 NS 
P significant < 0.05. 
                                               In Tables 8 & 9 – comparison of demographic, clinical 
parameters and SLEDAI between LAC detected Vs LAC not detected SLE patients 
show that recurrent abortions and aCL positivity were significantly higher in the 
former group. 
                                                              
                                                                    TABLE 9 
          Comparison of lab parameters – LAC detected VS LAC not detected patients 
 
s.
n
o 
Parameters LAC 
detected 
[N=13] 
% LAC not 
detected 
[N=97] 
% T-value P-value 
1 Hb in gms 
[mean±S.D] 
10.13±0.8
8 
 9.84±1.58  0.7359 NS 
Anaemia <10gms 
[no. of patients] 
5 38.46
% 
42 43.2
9% 
0.3311 NS 
2 Platelets in 
lakhs/cumm 
[mean±S.D] 
1.77±0.33  1.73±0.68  0.2082 NS 
Thrombocytopeni
a <1 lakh/cumm 
[no. of patients] 
0 0 9 9.3% 1.1462 NS 
3 ESR in mm/hr 
[mean±S.D] 
49.46±25.
38 
 57.8±32.8
3 
 0.8800 NS 
4 CRP positivity 
[no. of patients] 
10 76.92
% 
50 51.54
% 
1.7256 NS 
5 Anti – dsDNA 
positivity[no. of 
patients] 
4 30.77
% 
55 56.7
0% 
1.7607 NS 
6 aCL positivity 
[no. of patients] 
12 92.30
% 
14 14.43
% 
6.2062 0.0000
00005 
7 Low 
complement[no. 
of patients] 
7 53.85
% 
45 46.3
9% 
0.5055 NS 
8 SLEDAI score 
[mean±S.D] 
23.30±9.1
2 
 24.73±10.
09 
 0.4848 NS 
P significant < 0.05. 
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                           DISCUSSION  
                                         Systemic Lupus Erythematosus (SLE) is a chronic, 
autoimmune, multisystem disease which may affect the eyes and/or visual system in 
one third of patients. These ocular manifestations cause significant morbidity in their 
own right, but can also be a useful indicator of underlying systemic disease activity. 
Although early recognition and treatment have led to a reduction in severe ocular 
complications, ocular involvement in SLE is still a potentially blinding condition. 
                                                      The present study was done on 110 patients who satisfied the 
1997 ACR revised classification criteria for Systemic Lupus Erythematosus. There 
were 99 females and 11 males. The female to male ratio was 9 : 1. Indian series by 
Malaviya et al[67] had a female to male ratio of 8 : 1. 
                                                     The age of the patients varied from 9 years to 65 years. The 
mean age of the patients was 25.9±9.2 years. Disease onset in the second or third 
decade was common. Median age at disease onset was 21.32±5.38 years. Masi et al 
and Hochberg et al observed a median age of disease onset at 31 and 30 years 
respectively[63]. In India, Binoy J. Paul et al and Ghosh B et al noted a median age of 
onset of 21.6 and 26.5±9 years respectively[64,65]. The median disease duration of 
study patients was 29±30.8 months. About 12[10.9%] patients had childhood onset 
of disease. The mean disease duration in childhood onset SLE was 12.25±7.84 
months. 
                                          Musculoskeletal and mucocutaneous involvement were the 
commonest clinical manifestations noted in the study group as reported in studies 
from India and abroad[66,67]. 
                                            Ocular complaints were given by 23[20.9%] of patients. The 
common ocular complaints were blurring of vision in 12 patients[10.9%], dry eyes – 
3 patients[2.7%], red eyes – 3 patients[2.7%], swelling over eye lid – 2 patients[1.8%] 
, itching, eye discharge and  restriction of eye movements – each 1 patient[0.9%]. EY 
Yap et al[68], reported ocular symptoms in 7% of patients. 
                                            Keratoconjunctivitis sicca or dry eyes was the most common 
finding affecting 13 (11.8%) patients and is less than the figures found by Yap et al 
and other authors[69-71]. KIMURA ITARU et al also reported a prevalence of 32.5% of 
keratoconjunctivitis sicca in their study involving 329 patients[72]. There was no 
correlation between the presence of dry eyes and age, duration of disease, number or 
type of system involvement. This variable was independent and not related to any 
other parameters. Although the musculoskeletal system is linked to arthritis and 
collagen vascular disease, there was no significant correlation between the 
musculoskeletal system involvement and dry eyes.[73,74]   With an estimated 
prevalence of between 3 - 29%, retinal vascular lesions were  detected in 4.5% our 
patients.[75,76]              
                                                         Cotton wool spots were seen in 2.7% of our patients.  Gold 
et al[68] reported that 3% of ambulatory SLE patients had cotton wool spots. Shearn 
and Pirofsky and Lanham et[68] al found that 28%- 29% of hospitalised patients with 
SLE had retinal vascular findings[68]. 
                                                                                          The number of patients (3.6%) with steroid-induced 
cataracts was not comparable with the 20% reported by Yap et al. The presence of a 
cataract was not related to the duration of the disease, activity of the disease or the 
age of the patients. The cataracts were bilateral and were always associated with 
systemic steroid therapy. There was no case of corticosteroid induced glaucoma from 
our study population. 
                                             Optic neuropathy was seen in 0.9% of patients. This 
prevalence of clinical optic neuropathy is similar to the 1% - 2% reported in other 
series[68]. Optic neuropathy in SLE patients can present as optic neuritis, ischaemic 
optic neuropathy or slowly progressive visual loss[68]. 
                                                             Ocular movement abnormality due to lateral rectus palsy 
was seen in 0.9% of patients. Ocular motor signs in SLE are uncommon and often 
transitory. When present, they help to ascertain the location, and often the cause, of 
neurologic involvement[77].  
                                                                                             Chloroquine induced maculopathy was seen in 1.8% 
of our patients which is comparable with the reports of R Araiza-Casillas et al[78]. 
Infections of the eye are not common in our study. The common eye infections seen 
were blepharitis[0.9%], meibonitis[0.9%], conjunctivitis[0.9%], hordeolum 
internum[0.9%], herpes zoster ophthalmicus[0.9%] and dacryocystitis[0.9%]. 
                                                In our study, 12[10.9%]  childhood onset SLE patients 
were involved. Out of 12 patients 3[25%] had ocular involvement. One patient had 
herpes zoster ophthalmicus, another patient had cherry red spot with retinal 
vasculitis. One patient with associated APS had Gr II hypertensive retinopathy. In 
comparison with Al-Mayouf SM, Al-Hemidan AI. et al[79] study, which involved 52 
childhood SLE patients, ocular manifestations were less common in our study 
because of low number of childhood patients involved in the present study. The 
conclusion of their study was ocular manifestations including sight threatening 
complications are not rare in children with SLE and optic neuropathy has a strong 
prediction for CNS lupus. 
                                                                                   There exists no relationship between ophthalmic status 
of SLE patients, age of the patient and disease duration . 
                                                                                      There was a statistically significant difference in the 
parameters [table 4 & 5] between the patients who had ocular involvement and 
patients without ocular involvement in recurrent abortions, thrombocytopenia, Anti-
dsDNA positivity, aCL positivity, low complement levels and SLEDAI score which 
were significantly higher in the former group[with ocular involvement]. 
                                             In the present study the frequency of anticardiolipin 
antibodies was 23.6% and LAC positivity was 11.8%. Two studies from our country, 
in the north and Madras reported a frequency of 28% and 41% respectively for 
anticardiolipin antibodies.  
                                             In Tables 6 & 7 – comparison of demographic, clinical 
parameters and SLEDAI score between SLE patients with aCL positivity Vs aCL 
negativity show that recurrent abortions, ocular manifestations and LAC study were 
significantly higher in the aCL positive group. Ocular manifestations were seen in 
14[53.8%] of aCL positive patients. The common ocular abnormalities were dry eyes 
in 4[15.4%] patients, hypertensive retinopathy in 2[7.7%],retinal vasculitis in 
2[7.7%],posterior subcapsular cataract in 2[7.7%], CRAO with chloroquine 
maculopathy in 1[3.8%],optic atrophy in 1[3.8%],SCH in 1[3.8%], and retinal 
detachment with complicated cataract in 1[3.8%] patient. 
 
                                                       In Tables 8 & 9 – comparison of demographic, clinical 
parameters and SLEDAI between LAC detected Vs LAC not detected SLE patients 
show that recurrent abortions and aCL positivity were significantly higher in the 
former group. Ocular manifestations were seen in 6[46.2%] patients with positive 
LAC study. The common ocular manifestations seen were dry eyes 2[15.4%],SCH 
1[7.7%],optic atrophy 1[7.7%], retinal vasculitis 1[7.7%] and posterior subcapsular 
cataract  in 1[7.7%] patient with LAC positivity. 
                                          Only one patient had ocular manifestation as the first sign of 
SLE. The SLE patient with APS who had CRAO was found to have LAC  and aCL 
positivity which is similar to reports of previous studies[31]. Another patient with 
optic atrophy had LAC and aCL positivity which is similar to reports of  Lin et al.[42]   
. One patient presented with features of Steven Johnson syndrome like picture and 
was found to have  exudative retinal detachment of  both eyes, complicated cataract 
of left eye and  fibrovascular proliferative panuveitis of right eye with ANA and aCL 
positivity. Cystoid macular edema of both eyes was seen in one patient with SLE. No 
patient in our study had cavernous sinus thrombosis. 7.4% of SLE patients with APS  
had  hypertensive retinopathy. 
 
 
 
                            
 
 
 
    
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
                      CONCLUSION 
1] There was a female predominance in the patients with ocular involvement due to 
Systemic Lupus Erythematosus. 
2] Ocular manifestations were seen in 36.4% of our study patients. 
3]  Ocular complaints were given by 20.9% of patients. 
4] Keratoconjunctivitis sicca or dry eyes was the most common finding affecting 
11.8% of patients. Retinal vasculitis was seen in 4.5% of our patients. Posterior sub 
capsular cataract due to steroid use was seen in 3.6% of our patients. Chloroquine 
maculopathy was seen in 1.8% of our patients. 
5] Neuro-ophthalmic manifestations were less common involving 1.8% of our 
patients.     
6] Ocular infections involving 5.5% of our patients, were less common and are not 
life or vision threatening. 
7] There exists no relationship between ophthalmic status of SLE patients, age of the 
patient and disease duration . 
8] The frequency of anticardiolipin antibodies was 23.6% and LAC study was 11.8% 
in our patients. Their presence is positively correlated with ocular involvement. 
9] Ocular involvement is positively associated with recurrent abortions, 
thrombocytopenia, Anti-dsDNA positivity, aCL positivity, low complement levels and 
high SLEDAI score. 
10] Sight-threatening complications of SLE include optic neuropathy and retinal 
vascular disease. 
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                                        ABBREVATIONS  
ANA Antinuclear antibody 
Anti-ds DNA Anti double stranded antibody 
aCL IgM, IgG Anticardiolipin antibody IgM, IgG 
LAC Lupus anticoagulant 
C3, C4 Complement 
CRP C-reactive protein 
SLE Systemic Lupus Erythematosus 
cSLE Childhood SLE 
DLE Discoid Lupus Erythematosus 
ACR American College Rheumatology 
SLEDAI SLE Disease Activity Index 
APS Antiphospholipid Antibody Syndrome 
Anti-Sm Anti-Smith antibody 
CNS Central Nervous System 
CRAO Central Retinal Artery Occlusion 
CRVO Central Retinal Vein Occlusion 
BRAO Branch Retinal Artery Occlusion 
BRVO Branch Retinal Vein Occlusion 
ELISA Enzyme Linked Immunoabsorbant Assay 
S.D. Standard Deviation 
Hb Haemoglobin  
Grms Grams 
 
 
PATIENT  CONSENT  FORM 
STUDY TITLE 
Ocular manifestations of Systemic Lupus Erythematosus and Systemic Lupus 
Erythematosus with Antiphospholipid Syndrome.  
Study Centre   : Department of Rheumatology, 
Madras Medical College, Chennai – 600 003 
 
Patient’s Name  : 
Patient’s Age   : 
Identification Number  :                Patient may check (3 ) these boxes 
 
I confirm that I have understood the purpose of procedure for the above study. I have the 
opportunity to ask the question and all my questions and doubts have been answered to my 
complete satisfaction. 
 
 
I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time without giving any reason, without my legal rights being affected. 
 
 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the 
ethics committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study. 
 
 
I agree to take part in the above study and to comply with the instructions given during the 
study and to faithfully co-operate with the study team, and to immediately inform the study 
staff if I suffer from any deterioration in my health or well being or any unexpected or 
unusual symptoms. 
 
 
I hereby consent to participate in this study on “Ocular manifestations of Systemic 
Lupus Erythematosus and Systemic Lupus Erythematosus with 
Antiphospholipid Syndrome” 
 
 
I hereby give permission to undergo complete clinical examination and diagnostic tests 
including hematological, biochemical, radiological and urine examination. 
 
 
Signature / Thumb Impression ___________________ Place _________ Date ____________ 
Patient’s Name and Address: ___________________________________________________ 
Signature of the Investigator : ___________________ Place _________ Date ____________ 
Study Investigator’s Name : ________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                       PROFORMA 
                               Clinical Profile of Systemic Lupus Erythematosus 
NAME:                                                          AGE/SEX:                                   OP/ IP No:                          RCC 
No    : 
ADDRESS:                                                                  OCCUPATION: 
H/O PRESENT ILLNESS:                                                              TOTAL DURATION OF ILLNESS:                         
Fever                                    Malaise                                    Fatigue                                                        
Malar rash                           Discoid lesion                         Oral ulcer                           Alopecia                              
photosensitivity   
Purpura                                Raynaud’s                           Gangrene    
Joint Symptoms                          
Myalgia                              Weakness                                Headache                                dry eyes/red eyes 
Mood                                   Seizures                                    insomnia                                blurring of vision 
Swelling over eyelids      restriction of eye movements      
Chest pain                            Palpitation                               Dyspnoea                                Syncope                                
Pedal edema  
Cough                                    Expectoration                        Hemoptysis                             Hematuria                              
Oliguria                            Facial puffiness                                                   
OTHERS 
PAST HISTORY:                                                                            
PERSONAL HISTORY:                                                    
 
TREATMENT HISTORY: 
PHYSICAL EXAMINATION: 
Fever                Anaemia        clubbing         cyanosis      LN       PE      JVP          
MUCOCUTANEOUS  
OTHERS 
PULSE                                                    BP                                                 RR 
CVS                                                        RS                                                  ABDOMEN 
CNS                                                  MSS: 
Ophthalmic examination:     Right eye                Left eye 
  Visual Acuity 
  Lids 
  Ocular Movement 
  Conjunctiva  
  Cornea 
  Iris 
  Anterior Chamber 
  Pupils 
  Lens 
  Tension 
  N.L.Duct 
  Slit Lamp Exam 
  Retinoscopy 
  Fundus 
  Visual Field 
  Tonometry 
  Schirmer’s Test 
    
            
INVESTIGATIONS: 
Hb                    TC                   DC                        ESR 1 hr                Platelets                  BT                CT                    
PT          INR        APTT 
 
Urea               Cr                   Uric acid             Sugar              T.Bilirubin                   ALT                    AST 
SAP                  LDH               CPK                     Electrolytes       Na    K     HCO 3      Cl 
Lipid profile 
Urine R/E                                                                                               
ANA                                                                 Anti dsDNA                                 ACL 
LAC                                                                  VDRL                                             CRP  
Complement                                                   
 
ECG                                                                                         CXR PA View 
ECHO                                                                                        
ASSESSMENT 
SLEDAI                                                         SLICC 
MANAGEMENT 
NSAIDS                                                STEROIDS                Pulse                                         Oral 
IMMUNOSUPPRESSANTS                                                    ANTICOAGULANTS/ANTIPLATELETS        
 
 
 
 
 
 
 
 
 
 
 
     Systemic Lupus Erythematosus Disease Activity Index 
 
Descriptor Definition Weighted 
Score 
Seizure Recent onset; exclude metabolic, infectious, or 
drug-related causes 
8 
Psychosis Altered ability to function in normal activity owing 
to severe disturbance in the perception of reality; 
includes hallucinations, incoherence marked by 
loose associations, impoverished thought content, 
marked illogical thinking, and bizarre disorganized 
or catatonic behavior; exclude the presence of 
uremia and offending drugs 
8 
Organic brain 
syndrome 
Altered mental function with impaired orientation 
or impaired memory or other intellectual function, 
with rapid onset and fluctuating clinical features; 
includes clouding of consciousness with reduced 
capacity to focus and inability to sustain attention 
on environment, and at least two of the following—
perceptual disturbance, incoherent speech, 
insomnia or daytime drowsiness, and increased or 
decreased psychomotor activity; exclude metabolic 
infectious and drug-related causes 
8 
Visual Retinal changes from systemic lupus 
erythematosus cytoid bodies, retinal hemorrhages, 
serous exudate or hemorrhage in choroid, optic 
neuritis (not due to hypertension, drugs, or 
infection) 
8 
Cranial nerve New onset of sensory or motor neuropathy 
involving a cranial nerve 
8 
Lupus headache Severe, persistent headache; may be migrainous, 
unresponsive to narcotic analgesia 
8 
Descriptor Definition Weighted 
Score 
Cerebrovascular 
accident 
New syndrome; exclude arteriosclerosis 8 
Vasculitis Ulceration, gangrene, tender finger nodules, 
periungual infarction, splinter hemorrhages; 
vasculitis confirmed by biopsy or angiogram 
8 
Arthritis More than two joints with pain and signs of 
inflammation (tenderness, swelling, or effusions) 
4 
Myositis Proximal muscle aching or weakness associated 
with elevated creatine phosphokinase/aldolase 
levels, electromyographic changes, or biopsy 
specimen showing myositis 
4 
Casts Heme, granular, or erythrocyte 4 
Hematuria >5 erythrocytes per high-power field; exclude other 
causes (stone, infection) 
4 
Proteinuria >0.5 g of urinary protein excreted per 24 hr; new 
onset or recent increase of >0.5 g/24 hr 
4 
Pyuria >5 leukocytes per high-power field; exclude 
infection 
4 
New malar rash New onset or recurrence of inflammatory type of 
rash 
4 
Alopecia New or recurrent; patch of abnormal, diffuse hair 
loss 
4 
Mucous membrane New onset or recurrence of oral or nasal ulceration 4 
Pleurisy Pleuritic chest pain with pleural rub or effusion, or 
pleural thickening 
4 
Pericarditis Pericardial pain with at least one rub or effusion; 
confirmation by ECG or echocardiography 
4 
Low complement Decrease in CH50, C3, or C4 levels (to less than the 2 
Descriptor Definition Weighted 
Score 
lower limit of the laboratory-determined normal 
range) 
Increased DNA 
binding 
>25% binding by Farr assay (to more than the 
upper limit of the laboratory-determined normal 
range, e.g., 25%) 
2 
Fever >38°C after exclusion of infection 1 
Thrombocytopenia <100,000 platelets 1 
Leukopenia Leukocyte count <3000/mm3 (not due to drugs) 1 
ECG, electrocardiogram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
